



RECEIVED

APR 29 2002

12C
ENR
4-30-02
Patent

TECH CENTER 1600/2900

Attorney's Docket No. 003300-737

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Kjell OLMARKER *et al.*) Group Art Unit: 1647
Application No.: 09/760,810) Examiner: Jegatheesan Seharaseyon
Filed: January 17, 2001)
For: USE OF CERTAIN DRUGS FOR)
TREATING NERVE ROOT INJURY)

RESPONSE TO RESTRICTION REQUIREMENT, REPLY AND AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper response to the Restriction Requirement set forth in the Official Communication mailed March 26, 2002 (Paper No. 10).

Please amend the above-identified application as follows:

IN THE CLAIMS:

Please amend claims 1 and 2 as follows without prejudice or disclaimer.

c1 Jel D
1. (Amended) A method of treating a nerve disorder in a mammal in need of such treatment comprising the step of administering a TNF- α inhibitor wherein said TNF- α inhibitor is metalloproteinase inhibitors excluding methylprednisolone for the treatment of nerve disorders in said mammal in need of such treatment wherein said nerve disorder is caused by the liberation of TNF- α and compounds triggered by the liberation of or presence of TNF- α by inhibiting TNF- α .

2. (Amended) A pharmaceutical composition for the treatment of a nerve disorder in a mammal in need of such treatment comprising a pharmaceutically effective

04/29/2002 RMEBRAHT 00000053 09760810
252.00 op
01 FC:203
C